里程碑
-
2022
引进Bavarian Nordic全球同类首创 MVA-BN® RSV 呼吸道合胞病毒疫苗
引进Altamira Therapeutics用于预防过敏原与病毒防护的Bentrio™ 鼻喷剂
-
2021
引进Verona Pharma全球同类首创 COPD PDE 3&4 双重抑制剂 Ensifentrine
引进Aerogen Pharma新生儿呼吸窘迫综合征药械治疗组合 Aerofact™
收购中健药业（英联）100%股权，获得3款急救护理类产品及GSP管理资格认证
-
-
-
-
-
2022
2021
2020
2019
2018
2015
2014
-
2022
-
2021
-
2020
-
2019
-
2018
-
2015
-
2014
新闻
-
2023-04-06
Ensifentrine Completes Dosing of First Patient in ENHANCE - CHINA Phase III Trial for COPD
SHANGHAI, April 6, 2023 /PRNewswire/ -- Nuance Pharma ("the Company") announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") of its novel
-
2022-11-13
IND Approval for RSV Vaccine in China
SHANGHAI, Nov. 13, 2022 /PRNewswire/ -- Nuance Pharma announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal phase III clinical trial of MVA-BN RSV vaccine
-
2022-10-28
专访优锐医药：呼吸精品特药领域，如何打造现金“造血”教科书？
近日，动脉新医药访谈了优锐医药创始人兼CEO Mark Lotter先生。Mark Lotter曾是阿斯利康的首批来华高管，拥有超过20年的中国医疗行业市场经验。Mark Lotter与我们分享了优锐医药如何练就现金“造血”能力，并逐步成长为具有差异化的特药医疗公司。
